Session » (1877–1913) Epidemiology & Public Health Poster III

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1898

Assessing Representation in a Nation-Wide Psoriasis Registry: A Single-Institution Comparison

10:30AM-12:30PM: Abstract Number: 1895

Assessing the Validity of Self-Reported Medication Data Through Metabolite Analysis: Data from the Osteoarthritis Initiative

10:30AM-12:30PM: Abstract Number: 1900

Capturing Patient Cohorts: A Temporal Arteritis Classifier

10:30AM-12:30PM: Abstract Number: 1897

Changes in SLE Mortality During and After the COVID-19 Pandemic

10:30AM-12:30PM: Abstract Number: 1911

Characterizing Psoriasis Patients at Risk for Transition to Psoriatic Arthritis: Early Insights from the STOP PsA At-Risk Cohort

10:30AM-12:30PM: Abstract Number: 1908

Clinical and Imaging Features of Haemochromatosis Arthropathy – a Systematic Literature Review and Meta- Analysis

10:30AM-12:30PM: Abstract Number: 1910

Clinical profile and healthcare resource utilization of patients diagnosed with giant cell arteritis or polymyalgia rheumatica in the US: a real-world cohort study using a large database of administrative health claims

10:30AM-12:30PM: Abstract Number: 1878

Customized Therapy for SLE: How Disease Severity Influences the Use of Corticosteroids and Biologics in Patients with SLE in the Lupus Federated Data Network (LupusNet) and a US Claims Database

10:30AM-12:30PM: Abstract Number: 1912

Cutaneous manifestations of vasculitis: A cross-sectional analysis from an international cohort

10:30AM-12:30PM: Abstract Number: 1877

Demographics and trends of Inflammatory Arthritis-Related Mortality in the United States, 1999–2019

10:30AM-12:30PM: Abstract Number: 1888

Developing Machine Learning Algorithm in Electronic Health Record to Accurately Identify Psoriasis Patients

10:30AM-12:30PM: Abstract Number: 1913

Do We Screen For and Do We Miss Antimalarial-Induced Cardiomyopathy (AMIC)? Risk Profiles according to Hydroxychloroquine Exposure Duration

10:30AM-12:30PM: Abstract Number: 1896

Electronic Cigarette Use in Association with Risks of Developing Rheumatoid Arthritis or Systemic Lupus Erythematosus in the All of Us Research Program

10:30AM-12:30PM: Abstract Number: 1901

Epidemiology of Adult-Onset Still’s Disease in South Korea: A Nationwide Study Using Health Insurance Claims Data

10:30AM-12:30PM: Abstract Number: 1905

Exploring the Association Between Environmental Quality Index and Rheumatoid Arthritis Mortality in the United States

10:30AM-12:30PM: Abstract Number: 1891

Geographic Trends in the Burden of Gout in the United States from 1990 to 2021: A State-Level Analysis of Prevalence, Incidence, and Disability

10:30AM-12:30PM: Abstract Number: 1892

Impact of Systemic Lupus Erythematosus on In-Hospital Outcomes Following Percutaneous Coronary Intervention: Insights from a 7 year Nationwide Analysis

10:30AM-12:30PM: Abstract Number: 1887

Incidence, Prevalence and Mortality of Systemic Lupus Erythematosus – A 20-year territory-wide analysis of electronic health records in Hong Kong

10:30AM-12:30PM: Abstract Number: 1893

Increased Atrial Fibrillation Risk in Rheumatoid Arthritis: Greater in Seropositive Than Seronegative Patients

10:30AM-12:30PM: Abstract Number: 1879

Infections in Hospitalized Patients With and Without Psoriatic Arthritis (2016–2021): A National Inpatient Sample Study

10:30AM-12:30PM: Abstract Number: 1902

Investigating Factors Associated With Respiratory Syncytial Virus Vaccination and Breakthrough Infection Among Patients With Systemic Autoimmune Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 1904

Mapping CTD-ILD in a Spanish Cohort – the NIRRVANA Registry

10:30AM-12:30PM: Abstract Number: 1889

Navigating Diagnostic Challenges: Insights into the Patient Journey and Delays in Diagnosing Dermatomyositis from a Real-world Survey in the United States and Europe

10:30AM-12:30PM: Abstract Number: 1894

Opioid Use Disorder Among Patients with Rheumatic Conditions in the All of Us Research Program: A Descriptive Analysis

10:30AM-12:30PM: Abstract Number: 1890

Quantifying the Inflammatory Toll: Smoking-Attributable Rheumatoid Arthritis Burden Across the Globe, 1990–2021

10:30AM-12:30PM: Abstract Number: 1899

Regional Variability in SLE Damage Accumulation by Disease Activity Across the Lupus Federated Data Network (LupusNet)

10:30AM-12:30PM: Abstract Number: 1880

Rheumatoid Arthritis Mortality in the U.S. (1999–2020): A Decline in Rates, But Not in Disparities

10:30AM-12:30PM: Abstract Number: 1903

Seasonal and Racial/Ethnic Variation in Achieving Target Uric Acid Levels in Gout Patients on Urate Lowering Therapy in US Veterans in Central California

10:30AM-12:30PM: Abstract Number: 1885

Sex-specific Associations of Anthropometrics, Smoking and Eduction with the Risk of Rheumatoid Athritis: A Nested Case-Control Study

10:30AM-12:30PM: Abstract Number: 1881

Silent Impact: Two Decades of Sjögren’s Syndrome Mortality in the United States

10:30AM-12:30PM: Abstract Number: 1883

Temporal Patterns of Cardiometabolic Comorbidities Before and After Psoriatic Arthritis Diagnosis: A Nationwide Retrospective Study from Poland.

10:30AM-12:30PM: Abstract Number: 1884

The Importance of Adherence to Dietary Recommendations for Rheumatoid Arthritis Risk May Be Greater in Younger Individuals – Results from a Nested Case-Control Study

10:30AM-12:30PM: Abstract Number: 1906

The incidence and mortality of connective tissue diseases in England: a population-level cohort study from 2012 to 2023

10:30AM-12:30PM: Abstract Number: 1886

Thirty Percent of Older Adults with Rheumatic Disease Receive High-Risk Medication

10:30AM-12:30PM: Abstract Number: 1909

Trends of venous thromboembolism after total joint replacement in the United Kingdom after the introduction of NICE guidelines.

10:30AM-12:30PM: Abstract Number: 1907

Twenty-Year Trends in the U.S. Burden of Gout: A State-Level Analysis of Disability and Prevalence from 2001 to 2021

10:30AM-12:30PM: Abstract Number: 1882

Vessels Under Fire: National Mortality Trends in Systemic Vasculitides in the United States, 1999–2020

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].